Akebia Therapeutics (Akebia Therapeutics) GF Value : $1.02 (As of Apr. 28, 2024)

View and export this data going back to 2014. Start your Free Trial

What is Akebia Therapeutics GF Value?

The GF Value represents the current intrinsic value of a stock derived from our exclusive method. The GF Value Line on our summary page gives an overview of the fair value that the stock should be traded at. It is calculated based on three factors:

Historical multiples (PE Ratio, PS Ratio, PB Ratio and Price-to-Free-Cash-Flow) that the stock has traded at.
GuruFocus adjustment factor based on the company’s past returns and growth.
Future estimates of the business performance.

We believe the GF Value Line is the fair value that the stock should be traded at. The stock price will most likely fluctuate around the GF Value Line. If the stock price is significantly above the GF Value Line, it is overvalued and its future return is likely to be poor. On the other hand, if it is significantly below the GF Value Line, its future return will likely be higher.

Please note, "Possible Value Trap, Think Twice" is for the companies that look very undervalued, but either in the long term trend of business decline, or in financial distress.

As of today (2024-04-28), Akebia Therapeutics's share price is $1.34. Akebia Therapeutics's GF Value is $1.02. Therefore, Akebia Therapeutics's Price-to-GF-Value for today is 1.31.

Based on the relationship between the current stock price and the GF Value, GuruFocus believes Akebia Therapeutics is Significantly Overvalued.

Akebia Therapeutics (NAS:AKBA) GF Value Explanation

Based on the relationship between the current stock price and the GF Value, GuruFocus provides the following 6 evaluations:

Posssible Evaluations	All-in-One Screener Examples (2)
Possible Value Trap, Think Twice (1)	Predictable Companies that possibly be Value Traps
Significantly Overvalued	Predictable Companies which are Significantly Overvalued
Modestly Overvalued	Predictable Companies which are Modestly Overvalued
Fairly Valued	Predictable High Quality Companies which are Fairly Valued
Modestly Undervalued (3)	Predictable High Quality Companies which are Modestly Undervalued
Significantly Undervalued (3)	Predictable High Quality Companies which are Significantly Undervalued

(1) "Possible Value Trap, Think Twice" is for the companies that look very undervalued, but either in the long term trend of business decline, or in financial distress.

(2) These are some simple examples. You can access our GF Valuation filter under All-in-One Screener’s Fundamental tab, and Price-to-GF-Value filter under Valuation Ratio tab and set your own criteria.

(3) There is only a sufficient margin of safety when the stock is undervalued.

Akebia Therapeutics's Price-to-GF-Value for today is calculated as

Price-to-GF-Value	=	Share Price	/	GF Value
	=	1.34	/	1.02
	=	1.31

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Akebia Therapeutics GF Value Related Terms

Thank you for viewing the detailed overview of Akebia Therapeutics's GF Value provided by GuruFocus.com. Please click on the following links to see related term pages.

Akebia Therapeutics (Akebia Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Akebia Therapeutics Inc (NAS:AKBA) » Definitions » GF Value

Comparable Companies

Traded in Other Exchanges

AX9:Germany AX9:Germany

Address

245 First Street, Cambridge, MA, USA, 02142

Website

https://www.akebia.com

Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes 1) Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease. 2) Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor, is approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients. 3) HIF-PH inhibitors in preclinical development.

Executives

Ellen Snow	officer: SVP, CFO and Treasurer	C/O PEAR THERAPEUTICS, INC., 200 STATE STREET, 13TH FLOOR, BOSTON MA 02109
Michel Dahan	officer: SVP, Chief Business Officer	C/O AKEBIA THERAPEUTICS, INC., 245 FIRST STREET, SUITE 1100, CAMBRIDGE MA 02142
Nicole R. Hadas	officer: SVP, General Counsel, Sec.	20 PILGRAM DRIVE, WINCHESTER MA 01890
David A Spellman	officer: SVP, CFO and Treasurer	840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Steven Keith Burke	officer: SVP, Chief Medical Officer	82 WILLIS ROAD, SUDBURY MA 01776
John P. Butler	director, officer: CEO & President	C/O RELYPSA, INC., 700 SAGINAW DR., REDWOOD CITY CA 94063
Steven C Gilman	director	110 HARTWELL AVENUE, LEXINGTON MA 02421
Violetta Cotreau	officer: SVP, Chief Accounting Officer	245 FIRST STREET, 14TH FLOOR, CAMBRIDGE MA 02142
Ron Frieson	director	245 FIRST STREET, 14TH FLOOR, CAMBRIDGE MA 02142
Dell Faulkingham	officer: CCO	C/O AKEBIA THERAPEUTICS, INC., 245 FIRST STREET, CAMBRIDGE MA 02142
Leanne M Zumwalt	director	C/O THE ADVISORY BOARD CO WATERGATGE, 600 NEW HAMPSHIRE AVE NW, WASHINGTON DC 20037
Maxine Gowen	director
Cynthia Smith	director	508 WRANGLER DRIVE, SUITE 100, COPPELL TX 75019
Myles Wolf	director	C/O AKEBIA THERAPEUTICS, INC., 245 FIRST STREET, CAMBRIDGE MA 02142
Karen L Tubridy	officer: SVP, Chief Development Officer	ELEVEN BIOTHERAPEUTICS, INC., 215 FIRST STREET, SUITE 400, CAMBRIDGE MA 02142